https://www.selleckchem.com/pr....oducts/1-thioglycero
Samples from seven cases were further analysed using targeted sequencing, focusing on the exons of 409 key tumour suppressor genes and oncogenes. Bcl-2 /IGH-BCL2 tFLs do not have pathogenic mutations of epigenetic modifiers, such as EZH2, MLL2/KMT2D, MLL3/KMT2C, EP300, and ARID1A, which have been reported in FLs in the literature, whereas Bcl-2 /IGH-BCL2 tFLs are likely pathogenic/pathogenic missense mutations or frameshift mutations of these genes. Additionally, novel mutations in TET2 and EP400 were detected in Bcl-2 /IGH-BCL2
Like
Comment
Share
